Onconova Therapeutics Inc
ONTX
Get informed when a big investor buys or sells
+ FollowMarket Cap$20.9M
Close$
$0.86
13.4% downside
Current Fair Value
13.4% downsideOvervalued by 13.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $20.90 Million |
|---|---|
| Enterprise Value | $17.77 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.83 |
| Beta | 1.35 |
| Outstanding Shares | 10,640,625 |
Return
| Return on Equity | -172367.12% |
|---|---|
| Return on Assets | 112241.52% |
| Return on Invested Capital | 435.53% |
Valuation & Multiples
| P/E Ratio | -1.07 |
|---|---|
| PEG | 6.61 |
| Price to Sales | - |
| Price to Book Ratio | -1.0 |
| Enterprise Value to Revenue | 6.24 |
| Enterprise Value to EBIT | -0.81 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
April 15, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Onconova Therapeutics Inc
CEO: Steven Fruchtman